At a glance
ClinicalIndex Comparison Record- ✓Physically active at least 120 minutes per week
- ✓Age 18-35 years
- ✓Low cardiovascular risk by modified PAR-Q questionnaire, BMI, and non-smoking status
- ✓Normal pulmonary function with FVC, FEV1, and FEV1/FVC all ≥80% predicted
- ✕Current smoker
- ✕BMI >25 kg/m²
- ✕Any 'yes' answer to PAR-Q pre-participation questionnaire
- ✕History of pulmonary disease or FVC, FEV1, and/or FEV1/FVC <80% predicted
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia
In Brief
A Phase 4 clinical trial evaluating Cetirizine, Placebo oral capsule, and 1 other intervention for Hypoxia, Altitude. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.
Study Details
Timeline
Interventions
Cetirizine tablet 10 mg
Gelatin placebo
Exposure to a 14.3% oxygen environment simulating an altitude of 3,000m/9,000ft